{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:08:06Z","timestamp":1792267686812,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105543","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:18:46Z","timestamp":1758705526000},"page":"105543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation\/expansion multicenter study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"P.","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-2683","authenticated-orcid":false,"given":"J.","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gougis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-5067","authenticated-orcid":false,"given":"J.-Y.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-1106","authenticated-orcid":false,"given":"H.H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Doger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jeglinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"B.C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.esmoop.2025.105543_bib1","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers-a tumor-agnostic review of biology, diagnosis and targeted therapy activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105543_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108344","article-title":"RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives","volume":"242","author":"Addeo","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2025.105543_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932353","article-title":"RET signaling pathway and RET inhibitors in human cancer","volume":"12","author":"Regua","year":"2022","journal-title":"Front Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105543_bib4","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105543_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.esmoop.2025.105543_bib6","article-title":"Amplification of wild-type RET represents a novel molecular subtype of several cancer types with clinical response to selpercatinib","volume":"7","author":"Gandhi","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105543_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105543_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105543_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmoop.2025.105543_bib10","article-title":"A comprehensive overview of the relationship between RET gene and tumor occurrence","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105543_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ando.2024.02.001","article-title":"RET kinase inhibitors for the treatment of RET-altered thyroid cancers: current knowledge and future directions","volume":"85","author":"Hamidi","year":"2024","journal-title":"Ann Endocrinol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105543_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cancers16010031","article-title":"Selective RET inhibitors (SRIs) in cancer: a journey from multi-kinase inhibitors to the next generation of SRIs","volume":"16","author":"Clark","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105543_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105543_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105543_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-024-00563-4","article-title":"Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer","volume":"8","author":"Subbiah","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105543_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET fusion-positive non-small cell lung cancer: the evolving treatment landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2025.105543_bib17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1538-7445.AM2019-2199","article-title":"Abstract 2199: BOS172738: A novel highly potent and selective RET kinase inhibitor in phase 1 clinical development","volume":"79","author":"Keegan","year":"2019","journal-title":"Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105543_bib18","doi-asserted-by":"crossref","first-page":"TPS3162","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3162","article-title":"A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer","volume":"37","author":"Schoffski","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105543_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105543_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1523\/JNEUROSCI.4489-07.2008","article-title":"Retrograde signaling onto Ret during motor nerve terminal maturation","volume":"28","author":"Baudet","year":"2008","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105543_bib23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105543_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105543_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105543_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105543_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105543_bib28","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:28Z","timestamp":1777623088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925014127"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105543","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation\/expansion multicenter study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105543"}}